T he presence of underlying pulmonary disease in women of childbearing potential can present a significant challenge during the preconceptual period, pregnancy, and the postpartum period. Management of the underlying disease, recognizing and preventing disease progression, and, most important, managing and minimizing toxic side effects of various therapies during these phases require the expertise of an interdisciplinary team, involving close collaboration between intensive care physicians, pulmonary physicians, and high-risk obstetricians familiar with these disease states, in an effort to minimize fetal and maternal morbidity and mortality. Herein we review the impact of the pregnant state in lung transplant recipients, patients with pulmonary arterial hypertension, and patients with underlying cystic fibrosis.
Lung Transplantation and Pregnancy
In the past 2 decades, lung transplantation has emerged from the experimental arena and has now become a viable option for individuals with end-stage lung disease and pulmonary vascular disease refractory to medical therapy. Improved surgical techniques, advances in immunosuppression, and a better understanding of prophylaxis against infection have improved survival as well as quality of life for lung transplant recipients (1) . Often young women who undergo lung transplantation may regain normal fertility and potentially may become pregnant. Most transplantation centers advocate against pregnancy in lung transplant recipients because of uncertainty regarding the immunologic changes that may potentially affect graft function. If a female transplant recipient still seeks to become pregnant, the current recommendations are to postpone pregnancy for at least 2 yrs to assess graft function and the risk for developing obliterative bronchiolitis. This period also allows for stabilization of immunosuppressive mediations and rejection, since there is a limited 3-yr survival rate of 55% in this solid-organrecipient population (2, 3) . Females should be counseled extensively before conception regarding the possibility of graft dysfunction during pregnancy and the risk this poses to maternal survival.
The fact that a mother may not survive to see her child grow because of the nature of the limited survival of a lung transplant recipient must be discussed candidly with potential parents.
Safety of pregnancy in the female lung transplant recipient concerns three outcomes: maternal outcome, fetal outcome, and transplanted graft outcome. The majority of current data regarding pregnancy in the solid organ recipient and fetal outcomes comes mainly from the kidney transplantation population; pregnancy outcomes among thoracic organ transplant recipients are far less clear (4) . Until recently the majority of knowledge regarding lung transplantation and pregnancy was based on limited case reports or small case series. In 1991, the National Transplantation Pregnancy Registry (NTPR) was established to study the outcomes of pregnancies in all transplant recipients (5). The NTPR report indicated that among lung transplant recipients (n ϭ 11) who became pregnant, 48% experienced loss of graft function within 2 yrs of delivery. In comparison with data for other solid organ transplants, the risk of graft loss or rejection after pregnancy in lung transplant patients appears greater than that for other organ recipients. Possible reasons for the development of acute or chronic rejection of the lung graft in relation to pregnancy are likely multifold, including the increased need for immunosuppression during the pregnant state and poor graft surveillance due to a limited number of surveillance biopsies, in an effort to avoid radiation exposure early in pregnancy, and may allow for acute rejection to go undetected and untreated (6) . Other maternal complications have been reported, including the development of hypertension in pregnancy in 58% of patients, gestational diabetes in 17%, and rejection during pregnancy, occurring at a rate 36% higher than among both heart and pancreaskidney transplant recipients. In a subgroup analysis of eight pregnant lung transplant recipients, all eight reported at least one complication during pregnancy, including shortness of breath, rejection, and infection. The incidence of therapeutic abortions was also higher among the lung transplant recipients than among the heart and pancreas-kidney recipients, but spontaneous abortion was reported to occur at a lower rate.
Seven live births, with Ͼ55% of babies born preterm (Ͻ37 wks) were reported in the lung transplant group, with newborn complications occurring in approximately 71% of the seven babies, but no neonatal deaths were reported within 30 days of birth. It appears that a high incidence of low birth weight and prematurity, in comparison with the general population, is the standard for most babies born to solid-organ-transplant recipients, but there is no evidence of specific malformations in these offspring. At followup, all the children born to lung transplant recipients were developing well, with no evidence of further complications.
Great concern usually exists regarding the effects of immunosuppressive medications on fetal outcome, especially among lung transplant recipients, for whom a complex triple-drug regimen-a combination of a calcineurin inhibitor, cell modulator, and prednisone-is usually maintained for a lifetime and at higher levels than for other solid organs transplants. Although limited pregnancy outcome data are available for the immunosuppressive regimen used in lung transplantation, no specific malformations have been noted through data from the NTPR report. For the classic immunosuppressants, including cyclosporine A, azathioprine, and steroids, it is likely that therapy has no adverse effects on the fetus. However, the safety of the newer medications such as mycophenolate mofetil is far from determined, and some concern has been raised over risk of birth defects and/or spontaneous miscarriage in women exposed to the drug (7). Although limited data exist regarding lower incidences of preeclampsia and hypertension in liver and heart transplant patients receiving tacrolimus, there are few data regarding the safety and risk of intrauterine restriction with its use in lung transplantation (8) . Because of the apparent decreased incidence of preeclampsia noted in other solid organ transplant recipients, isolated case reports about the use of tacrolimus in lung transplant patients have emerged, advocating the use of tacrolimus as the immunosuppressant of choice for pregnant lung transplant recipients (9) .
Calcineurin inhibitor doses should be kept the same or increased, with regular surveillance of levels during pregnancy because of the increased risk of rejection in the lung transplant population. It is not uncommon for immunosuppressive drug levels to drop during the pregnant state because of the increase in plasma volume and alteration in drug metabolism (10, 11) . Close attention must be paid to the development of hypertension, preeclampsia, and renal dysfunction during the pregnant state. Close monitoring for maternal viremia, especially that due to herpes simplex virus and cytomegalovirus, should be performed routinely. Surveillance monitoring of graft function by pulmonary functioning testing and, if indicated, by bronchoscopy may be necessary because of the risk of rejection during pregnancy. It is the general recommendation that prenatal visits occur every 2 wks up to 32 wks and then weekly thereafter, with close monitoring by an interdisciplinary team of both transplantation physicians and high-risk obstetrical specialists (12) .
Pulmonary Arterial Hypertension and Pregnancy
Pulmonary arterial hypertension is a life-threatening disorder that refers to a group of diseases characterized by an abnormal elevation of blood pressure within the pulmonary circulation, due to vasculopathy of the pulmonary microcirculation. Pulmonary arterial hypertension has been defined as a mean pulmonary artery pressure Ͼ25 mm Hg at rest or 30 mm Hg during exercise (13) . If it is left untreated, the overall prognosis of pulmonary arterial hypertension is poor, with a 5-yr survival rate of 34% in the case of idiopathic pulmonary hypertension. The most common cause of death is progressive right-sided heart failure. There is no pharmacologic cure for pulmonary arterial hypertension, and a team approach is required for the proper care of women with this rare condition who become pregnant.
Causes of pulmonary arterial hypertension include primary pulmonary hypertension and other vascular arterial pulmonary diseases due to chronic thromboembolic disease, connective tissue diseases such as scleroderma, and side effects from certain drugs such as anorectic agents. Irrespective of the etiology, pulmonary arterial hypertension carries a high mortality during the pregnant state (13) .
Idiopathic pulmonary arterial hypertension or primary pulmonary hypertension is more common in women of childbearing age and is characterized by a progressive increase in pulmonary artery pressure without an identifiable cause. The most common cause of pulmonary hypertension in women of childbearing age, though, is a large cardiac shunt at any level (Eisenmenger syndrome) (14) .
Significant cardiopulmonary changes occur during the pregnant state and puerperium, causing significant clinical changes in patients with pulmonary arterial hypertension and accounting for high maternal mortality. During the normal pregnant state, due to an increase in oxygen consumption, almost a 50% increase in blood volume and subsequent increase of 30%-50% in cardiac output occur, along with a decline in systemic vascular resistance. An increase in pulmonary blood flow also occurs, with compensation through dilation of the pulmonary vasculature, resulting in decreased pulmonary artery pressures (15) .
These physiologic changes generally occur early in the pregnant state, peak during the second trimester, and remain constant during the remainder of the pregnancy until delivery. Immediately after delivery a 500-mL autotransfusion occurs from the involuting uterus, increasing the maternal blood volume further and increasing the volume returned to the right ventricle. Further increasing the return of blood to the right ventricle is the absence of the gravida uterus, which no longer causes obstruction to caval venous flow. Other factors contributing to alteration of hemodynamics during delivery include pain, anxiety, elevated catecholamine levels, and uterine contractions (16) . During this state the cardiac output continues to increase but the pulmonary and systemic vascular resistance remain decreased for 48 -72 hrs in the normal patient. In the patient with pulmonary arterial hypertension, there is a limited ability to compensate for this almost half-fold increase in cardiac output and blood volume because of the fixed resistance of the pulmonary vasculature, which eventually leads to acute right ventricular failure. In addition, reduced left ventricular filling can also result from right ventricular failure, leading to lowoutput heart failure as well.
Subsequent development of maternal hypoxia and hypercapnia can result, further increasing pulmonary vascular resistance and leading to the rapid onset of severe right ventricular failure and cardiac arrest. The described physiologic changes occur at the times of highest risk of death from pulmonary hypertension, which are usually immediately after delivery and in the first 72 hrs postpartum (17) .
The maternal mortality rate among parturients with idiopathic pulmonary hypertension is approximately 30%. Weiss et al. (18) determined the mortality from secondary pulmonary arterial hypertension to be 56%, from a review of cases of pulmonary arterial hypertension during pregnancy that were reported from 1978 to 1996. Factors leading to a better prognosis in this cohort were early diagnosis of pulmonary vascular disease and earlier hospitalization during the pregnancy. Overall, maternal mortality risks have not changed greatly over the past 2 decades, as noted by from this review (18) .
In patients with severe pulmonary arterial hypertension with pulmonary artery pressure Ͼ60 mm Hg and right ventricular dilation, pregnancy and delivery are very poorly tolerated, leading often to right ventricular collapse after delivery (19) . In the largest review of Eisenmenger syndrome, by Gleicher et al. (20) , the investigators reported that in 70 documented pregnancies, 52% of all patients died in connection with pregnancy, with no difference in maternal mortality between first, second, and third pregnancies. Therefore, women should be counseled that successful outcome with one pregnancy does not secure a similar outcome of subsequent pregnancies. In this review maternal mortality was highest again during parturition and during puerperium. Offspring also did not fare well: (20) . A more recent series report from Avila et al. (21) noted slightly improved maternal and fetal outcomes for patients with Eisenmenger syndrome in 13 pregnancies, in which two maternal deaths occurred before 28 wks' gestation and only seven pregnancies reached the end of the second trimester (21) .
The treatment and care of the patient with pulmonary arterial hypertension during pregnancy can be challenging and is best undertaken at referral centers that can manage this unique state with a multidisciplinary-team approach. Premature delivery and fetal mortality are also increased among these patients, such as those with Eisenmenger syndrome, in which premature delivery may occur in up to 50% of cases and only 15%-25% of pregnancies are carried to term. Recognition of the increase in both the fetal and maternal mortality rates among patients with pulmonary arterial hypertension has led physicians to recommend effective contraception and, in cases of pregnancy, early fetal termination. Effective contraception in this population usually involves tubal ligation, levonorgestrel-releasing intrauterine devices, or progesterone-only pills to avoid the potential thrombophilic potential of combination or estrogen-containing oral contraception. An alternative for women who desire children is the use of assisted reproductive technologies and a gestational carrier; however, the ovarian stimulation and oocyte retrieval are not without risks, which include ovarian hyperstimulation syndrome leading to pulmonary edema and multiple organ failure (22, 23) .
For patients with pulmonary arterial hypertension who continue with the pregnancy, hospitalization at 20 wks and close monitoring are recommended, with early accurate dating of the pregnancy by first-trimester ultrasound in an effort to prepare far in advance for delivery preparations since it may be difficult to determine which patients' conditions will deteriorate in pregnancy. Repeated ultrasonography is recommended to assess for intrauterine growth retardation, which has been associated with maternal cyanosis, hypoxemia, and elevated hematocrit levels. Intrauterine growth retardation has been reported to occur in 33% of cases of pulmonary hypertension, especially in patients with antiphospholipid antibodies and lupus-associated pulmonary artery hypertension (17) .
Limited physical activity, low salt intake, and careful use of diuretics may reduce volume overload in patients with right ventricular failure. Arterial blood gas determinations and supplemental oxygen may be needed to carefully monitor and support patients who are at risk for hypoxia, in an effort to avoid further increases in pulmonary vascular resistance. In addition, the diagnosis of obstructive sleep apnea should be aggressively pursued and the condition treated to avoid nocturnal hypoxia, which may aggravate pulmonary pressures further (24) . Modest increases in the cardiac output and improvement in right heart failure may be seen with the use of cardiac glycosides such as digoxin. Heparin (pregnancy category C) is recommended for use throughout the pregnancy, or at least during the third trimester and early postpartum period, because of the increased risk of thromboembolism in patients with pulmonary artery hypertension. Warfarin (pregnancy category X) is considered teratogenic and should be avoided during pregnancy.
Since pulmonary vasoconstriction is the prominent feature of pulmonary arterial hypertension, the use of vasodilator therapy may improve pulmonary blood flow. The successful use of calcium channel blockers during pregnancy has been reported. In addition, inhaled nitric oxide has been used in the predelivery and postdelivery management of pulmonary artery hypertension, as demonstrated by a reduction in pulmonary artery pressures during direct cardiac catheterization (25) . Limitations of the use of nitric oxide include poor tolerance of administration by face mask, platelet inhibition, methemoglobinemia, and possible formation of toxic nitrite metabolites, as well as the high cost associated with its use (26) .
Epoprostenol or prostacyclin (pregnancy category B) has now become a mainstay in the long-term treatment of primary pulmonary hypertension or pulmonary arterial hypertension. In at least three major randomized controlled trials, the continuous intravenous infusion of epoprostenol, a synthetic salt of prostacyclin with potent vasodilatory ability, has been shown to improve exercise tolerance, hemodynamics, survival, and quality of life for patients in New York Heart Association functional classes III and IV with either primary pulmonary hypertension or pulmonary arterial hypertension (27, 28) . Epoprostenol has also been noted to inhibit platelet aggregation and has mild effects on uterine blood flow; however, several reports have described the use of intravenous epoprostenol therapy during parturition and after delivery as being associated with good outcomes and no fetal deformities or growth retardation during the last trimester of pregnancy (29) .
Nevertheless, epoprostenol is far from an ideal form of therapy. Issues such as the short half-life of the drug, need for continuous central intravenous access, and significant side effects have led to the development of more stable prostacyclin analogues as alternative therapeutic agents for primary pulmonary hypertension. These alternatives include iloprost (inhaled delivery) and treprostinil (subcutaneous delivery). As a result, the U.S. Food and Drug Administration recently approved treprostinil (pregnancy category B) for the treatment of pulmonary arterial hypertension in patients in New York Heart Association functional classes II-IV. The use of inhaled iloprost is not recommended in pregnancy because of reports of digital abnormalities in rat fetuses, but it has been used to manage pulmonary hypertension in the immediate postpartum period (16, 30) . However, case reports of the use of inhaled epoprostenol in pregnancy seem to suggest that this agent reduces pulmonary artery pressures more effectively than intravenous epoprostenol or inhaled nitric oxide. Side effects of intravenous epoprostenol, including bleeding due to inhibition of platelet aggregation and systemic hypotension, are avoided by using the inhaled preparation as well (31) . In one reported case of postpartum bleeding due to platelet inhibition secondary to intravenous epoprostenol, effective bleeding control occurred after the patient was switched from intravenous epoprostenol to inhaled epoprostenol (32) . Endothelin-1 is also a potent vasoconstrictor, and increased levels have been found in patients with primary pulmonary hypertension. Bosentan is the first endothelin receptor antagonist to be approved by the Food and Drug Administration for the management of pulmonary arterial hypertension, but the safety of this drug in pregnancy has not been established, and therefore its use is contraindicated in pregnancy (pregnancy category X) (33).
Roberts et al. (5, 34) have been able to provide some prognostic data on pregnant pulmonary hypertension patients, 5, 34) . Overall, pulmonary artery catheterization may provide early warning regarding a rise in pulmonary artery pressure, impending right ventricular failure, and the effects of the various therapies, but its use has not been associated with improved survival, and the risk of pulmonary artery rupture does exist (16) . However, despite no improvement in survival, most experts recommend pulmonary artery catheterization during the intrapartum and postpartum periods. In addition, echocardiography has been noted to overestimate actual pulmonary artery systolic pressures in the pregnant patient because of an increase in vena cava size (due to increased blood volume) and to overestimate right atrial pressures, and when used alone it may be unreliable in estimating pulmonary artery pressures (35) .
The goal for management of delivery includes avoiding increases in pulmonary vascular resistance and maintenance of right ventricular preload. Adequate analgesia is of paramount importance to avoid maternal hypoxia, hypercapnia, and acidosis, which can worsen pulmonary vascular resistance, and analgesia is usually best provided by epidural anesthesia.
Vaginal delivery appears to be better tolerated than cesarean delivery by pregnant women with pulmonary arterial hypertension, although there are a limited number of case reports of successful cesarean deliveries with good maternal and fetal outcomes. Still, the mode of delivery in this population depends primarily on specific obstetrical indications and careful planning on the part of anesthetists, intensivists, and the obstetrical team. After delivery patients should be monitored closely hemodynamically and electrocardiographically for at least 72 hrs to prevent deterioration and right ventricular failure due to increased venous return (32, 36) .
Cystic Fibrosis and Pregnancy
Cystic fibrosis (CF) is the most common, classic Mendelian autosomalrecessive, life-limiting disease among whites. It is a multiple-system disease that results from loss of function in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, classically leading to respiratory tract, gastrointestinal, pancreatic, and reproductive abnormalities (37, 38) . CF was recognized as a distinct clinical entity in 1938 and was thought to be invariably fatal during infancy. Over the past 30 yrs, the life span of patients with CF has been prolonged, with advances in early diagnosis (e.g., newborn screening); care (i.e., meconium ileus management and methods for sputum clearance and managing respiratory failure); and disease therapy (i.e., improved antibiotics/macrolides, better pancreatic enzymes). With current management, almost 80% of patients with CF will reach adulthood, further highlighting the fact that CF is no longer a purely pediatric disease. For patients born in the 1990s, the median survival is predicted to be Ͼ40 yrs (39 -41) .
As more patients with CF are surviving longer, adult issues such as careers, relationships, and family are becoming important. Since many more patients with CF are surviving into their 40s, issues of family and children have gained more attention (42) .
Most males with CF are infertile because of aspermia secondary to atretic or bilateral absence of the vas deferens and/or seminal vesicle abnormalities (43) . It is believed that during fetal life, the vas deferens becomes plugged with mucoid secretions and subsequently gets reabsorbed. Libido and sexual performance are not affected. Artificial insemination may be used for couples desiring offspring, by obtaining microscopic epididymal sperm samples. Females with CF usually have normal reproductive tracts, although the cervical mucus may be tenacious as a result of CFTR mutation, thus blocking the cervical canal and possibly interfering with fertility. The endometrium and fallopian tubes contain very small amounts of CFTR and usually remain normal. Onset of menarche is usually normal except in females who are severely ill and undernourished (44) . Overall, females with CF are not as infertile as their male counterparts, and birth control must be discussed with female patients reaching sexual maturity. In addition, preconception counseling is also important in that analysis of the spouse's CF carrier state and hereditary pattern can be analyzed to improve neonatal outcome (45) .
Since the 1960s, the prognosis for CF and pregnancy has improved greatly. Maternal deaths usually occur with the most severe lung disease. More recent data seem to suggest that pregnancy risk correlates with disease severity. Although CF is a systemic disorder that may affect pregnancy, the state of the respiratory system and pulmonary functioning are the most important factors that may contribute to the morbidity and death of the pregnant patient with CF (46) .
One study report by Canny et al. (47) recommended a forced expiratory volume in 1 sec (FEV 1 ) value Ͼ70% as a requirement for a successful pregnancy outcome. Although there are no absolute guidelines, several parameters have been suggested to predict a poor maternal outcome, including pregravid forced vital capacity Ͻ60% and FEV 1 Ͻ70% (46).
Termination of pregnancy has been recommended if the FEV 1 is Ͻ50%; however, reports do exist of successful pregnancies with low FEV 1 values (48) . In fact, reports from the Toronto CF center indicated that several patients with FEV 1 of 35% of predicted value maintained their pulmonary status for several years after delivery, underscoring the importance of not using the FEV 1 value alone for determination of pregnancy termination (49) . The presence of pulmonary hypertension as a late consequence of severe CF is considered a contraindication to pregnancy, and in such cases either counseling against pregnancy or therapeutic abortion is advocated (50) .
Extremes of low body weight have resulted in terminations and premature deliveries and may be a relative contraindication (51) . In addition, pancreatic insufficiency was thought to be a contraindication to pregnancy in the past, but because of improved nutritional aids, more pancreatic-insufficient patients with CF have been reported to have successful pregnancies. In patients with CF and diabetes mellitus, factors such as gestational diabetes, the presence of Burkholderia cepacia, and frequent infectious exacerbations may contribute to significant adverse outcomes such as premature delivery and complications for the mother and baby (45, 50) .
The CF National Patient Registry database shows no difference in the rate of hospital admissions, use of home intravenous antibiotics, use of supplemental oxygen, or use of supplemental nutrition 1 yr after pregnancy (52) . Therefore, it seems that women with CF who become pregnant do not have a poorer survival than nonpregnant females with CF.
It is recommended that during pregnancy, patients with CF routinely visit CF units on a bimonthly basis for sputum culturing, evaluation, and treatment. During these visits, extended lung function testing should be performed and medications adjustments should be made; regimens of oral, inhaled, and systemic antibiotics should be adjusted routinely. Drug safety reviews, involving medication interactions, teratogenicity, and embryotoxicity, should also be done at these bimonthly visits. Adequate blood sugar control and chest physiotherapy should be continued as well.
The most common neonatal complication is premature delivery, which occurs in up to 24% of patients with severe CF disease and in patients with complications such as severe lung disease, diabetes, and liver disease. Otherwise, obstetric complications are no more frequent in pregnant patients with CF than in pregnant patients without CF.
In terms of infant health, it should be kept in mind that all infants will be carriers of a maternal gene for CF. Case reports have noted fetal anomalies caused by treatment or maternal complications or by chance itself. Data from the Toronto CF center indicate that, in general, good fetal outcome can be expected in the majority of cases (49) .
